Navigation Links
ALS Therapy Development Institute: More Burrito!
Date:3/31/2009

Area Cyclists to Eat Only From Local Taqueria in Preparation for 270 Mile Bike Trek

CAMBRIDGE, Mass., March 31 /PRNewswire-USNewswire/ -- Beginning April 1st, three passionate Boston bicyclists will eat every lunch and every dinner for the next 30 days at the well-known Anna's Taqueria restaurant as part of their training for the 270 mile charity bike ride, Tri-State Trek. Documenting their experiences on the social networking sites Twitter and Facebook, Richard Starry of Allston, Ian Schaefer of Allston, and Mike Rubino of Boston hope to raise global awareness for the Trek's cause, ending ALS (amyotrophic lateral sclerosis), also known as Lou Gehrig's disease.

"I'll do whatever I can to let people know about this bike ride and our mission to end ALS," says Richard (Ric) Starry, Service Manager at Eastern Mountain Sports and lead bicycle technician for the Trek. "Besides, their food is delicious and it's easy to make healthy choices," says Starry. "If eating 60 burritos will bring more attention to the disease, more riders to the cause and more money to research then I'll take super chicken, guac, no sour!"

All proceeds from the Tri-State Trek benefit research into treatments for ALS, a progressive neurodegenerative disease that affects 5,000 Americans each year. For more information on the Trek or to follow Ric, Ian, and Mike on Twitter and Facebook visit the Tri-State Trek's website at www.TriStateTrek.com.

About the Tri-State Trek

The Tri-State Trek is a three-day, 270 mile bicycle ride from Boston to New York that raises money for the ALS Therapy Development Institute. The event started with just 16 riders in 2003 and has grown through word of mouth. In 2008 the group rode 185 strong, raised almost half a million dollars, and brought a six year total to over $1.2 million.

The 7th annual Tri-State Trek takes place this July 24, 25, 26. For more information please visit www.TriStateTrek.com.

About ALS TDI

The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that stop ALS as soon as possible. Focused on meeting this urgent unmet medical need, ALS TDI executes a robust discovery program, as well as a multi-pronged approach to validate potential therapeutics; including small molecules, protein biologics, gene therapies and cell-based constructs. The Institute's unique, industrial-scale platform allows for the development and testing of dozens of potential therapeutics each year. Built by and for patients, the Institute is the world's only non-profit biotechnology company with more than 30 professional scientists. In addition, the Cambridge, Massachusetts based research Institute collaborates with leaders in both academia and industry. For more information, please visit us online at www.als.net.

    CONTACT: Robert Goldstein
    ALS TDI
    617-441-7295
    rgoldstein@als.net


'/>"/>
SOURCE ALS Therapy Development Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Study examines the use of light in medical therapy
2. VIDEO from Medialink and Bausch & Lomb: Bausch & Lomb Partners With Visual Therapy to Help Women Nationwide See a New You
3. Bausch & Lomb Partners With Visual Therapy to Help Women Nationwide See a New You
4. Thomson Reuters Study Finds Step Therapy Programs May Increase Overall Healthcare Costs for Employers
5. High dosage brachytherapy obtains excellent results in head and neck tumors
6. 3-drug chemotherapy combination increases organ preservation in patients with larynx cancer
7. House Republican Leader Boehner Says CMS Policies on Home Oxygen Therapy Will Potentially Harm Care Available to Medicare Beneficiaries
8. Epiphany Biosciences Initiates Program to Assess Valomaciclovir (EPB-348) as Adjunctive Therapy in Multiple Sclerosis (MS)
9. NICE SUGAR: Intensive insulin therapy risks
10. New stem cell therapy may lead to treatment for deafness
11. 2-day results predict ultimate response to therapy in chronic hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Northridge ... now offering treatments for sleep apnea and TMJ at their office. TMJ, or ... , specifically the obstructive type, is increasingly being treated at dental offices with ...
(Date:3/24/2017)... ... 2017 , ... Viewers who like to educate themselves on current issues and ... services, and societal issues tend to appreciate and love the "Informed" series, hosted by ... running events for causes around the world. , Running for charity has ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... first Certified Medical Reiki™ Master in Frederick, MD. Judy says, “I am passionate ... during what is often a very difficult and challenging time.” , A Certified ...
(Date:3/24/2017)... ... March 24, 2017 , ... “Vintage and Harvest A Cultivation of ... college Bible teacher residing in North Carolina with his wife, Anna Marie. He and ... with six grandchildren. David is also the author of “Shadow and Substance.” , “Love, ...
(Date:3/23/2017)... ... 23, 2017 , ... In 2016 the World Health Organization declared the Zika ... million Zika-related cases in the Americas within the next year. Lyme disease is one ... year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and other insect borne illnesses ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Oregon and PUNE, India , March 24, 2017 ... Research, titled, "Spine Bone Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," ... is projected to reach $724 million by 2022, growing at a CAGR of ... ... Allied Market Research Logo ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... This report analyzes the worldwide markets for Dental Implants in US$ Million. ... , Japan , Europe , ... Rest of World. Annual estimates and forecasts are provided ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... to their offering. ... IPF pipeline is very strong with a total of 97 drug candidates. ... and Sanofi are involved in the development of the IPF therapeutics. The ... Phase III stage, 15 are in Phase II stage, 12 are in ...
Breaking Medicine Technology: